New drug cocktail aims to tackle childhood cancers that Won't quit
NCT ID NCT06006273
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing whether adding a drug called eribulin to two standard chemotherapy drugs (irinotecan and temozolomide) is safe for children and young adults up to age 25 with solid tumors that have returned or not responded to treatment. The main goal is to find the best dose of eribulin for this combination. About 48 participants will be enrolled, and researchers will closely monitor side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- eribulin, irinotecan, and temozolomide
- What this could lead to
- If successful, this could point toward a new treatment option for children with hard-to-treat solid tumors that have come back or not responded to standard therapy.
- What could go wrong
- This is an early phase 1 trial with only 48 participants, focused on safety and dosing—not yet on effectiveness. The combination may cause significant side effects and may not shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.